抑制B细胞受体信号通过RAC2破坏套细胞淋巴瘤细胞黏附
本研究探讨B细胞受体(BCR)信号与细胞黏附的关联,发现套细胞淋巴瘤(MCL)细胞系对依鲁替尼的敏感性与细胞黏附表型相关;依鲁替尼仅在敏感细胞中下调BCR和黏附特征及RAC2,RAC2与BLNK结合,RAC2减少损害黏附,过表达逆转依鲁替尼效应;小鼠模型中依鲁替尼减缓肿瘤生长并降低组织RAC2,约65%人原发MCL肿瘤表达RAC2。
要点
- 依鲁替尼敏感性MCL细胞中BCR与黏附特征同步下调,RAC2在RNA和蛋白水平降低。
- RAC2与BLNK在敏感细胞中物理结合,RAC2减少损害细胞黏附。
- RAC2在约65%人原发MCL肿瘤中表达,依鲁替尼抑制RAC2导致黏附受损。
核心结论
- BCR信号通过RAC2调控MCL细胞黏附,RAC2和细胞黏附在MCL发病及药物开发中具重要性。
研究设计与样本
- 研究使用MCL细胞系、异种移植小鼠模型和人原发淋巴瘤肿瘤,结合RNA测序、RNA干扰和CRISPR等方法。
主要发现
- MCL细胞系对依鲁替尼的内在敏感性与细胞黏附表型相关。
- 依鲁替尼仅在敏感细胞中同时下调BCR和细胞黏附特征,并在RNA和蛋白水平降低RAC2。
- RAC2仅在敏感细胞中与BCR衔接蛋白BLNK物理结合。
- RNA干扰和CRISPR减少RAC2损害细胞黏附,RAC2过表达逆转依鲁替尼诱导的黏附损害。
- 异种移植小鼠模型中依鲁替尼治疗减缓肿瘤生长并降低组织RAC2表达;约65%人原发MCL肿瘤表达RAC2。
临床怎么用
- 依鲁替尼通过抑制BCR信号下调RAC2,进而破坏MCL细胞与微环境的黏附。
- RAC2表达和细胞黏附表型可能作为MCL对依鲁替尼敏感性的参考指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inhibition of the B-cell receptor (BCR) signaling pathway is highly effective in B-cell neoplasia through Bruton tyrosine kinase inhibition by ibrutinib. Ibrutinib also disrupts cell adhesion between a tumor and its microenvironment. However, it is largely unknown how BCR signaling is linked to cell adhesion. We observed that intrinsic sensitivities of mantle cell lymphoma (MCL) cell lines to ibrutinib correlated well with their cell adhesion phenotype. RNA-sequencing revealed that BCR and cell adhesion signatures were simultaneously downregulated by ibrutinib in the ibrutinib-sensitive, but not ibrutinib-resistant, cells. Among the differentially expressed genes, RAC2, part of the BCR signature and a known regulator of cell adhesion, was downregulated at both the RNA and protein levels by ibrutinib only in sensitive cells. RAC2 physically associated with B-cell linker protein (BLNK), a BCR adaptor molecule, uniquely in sensitive cells. RAC2 reduction using RNA interference and CRISPR impaired cell adhesion, whereas RAC2 overexpression reversed ibrutinib-induced cell adhesion impairment. In a xenograft mouse model, mice treated with ibrutinib exhibited slower tumor growth, with reduced RAC2 expression in tissue. Finally, RAC2 was expressed in ∼65% of human primary MCL tumors, and RAC2 suppression by ibrutinib resulted in cell adhesion impairment. These findings, made with cell lines, a xenograft model, and human primary lymphoma tumors, uncover a novel link between BCR signaling and cell adhesion. This study highlights the importance of RAC2 and cell adhesion in MCL pathogenesis and drug development.
引用
- Wu W, Wang W, Franzen CA, et al. Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2. Blood Adv. 2021. PMID: 33570628. doi:10.1182/bloodadvances.2020001665
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。